Oct 24, 2019 by Brian Orelli, PhDHere's Why Rigel Pharmaceuticals Jumped Another 17% TodayThe cheap biotech is showing signs of growth.
Oct 21, 2019 by Brian Orelli, PhDHere’s Why Seattle Genetics Climbed Higher TodayPositive clinical trial data for its breast cancer drug tucatinib has investors smiling.
Oct 15, 2019 by Brian Orelli, PhDHere's Why Reata Pharmaceuticals Skyrocketed Higher TodayData from a phase 2 study looks promising.
Oct 10, 2019 by Brian Orelli, PhDHere's Why Stealth BioTherapeutics Rocketed Higher TodayThe clinical-stage biotech made a new friend.
Oct 8, 2019 by Brian Orelli, PhDHere's Why Qiagen Plummeted TodayA trio of news items has the healthcare company in transition.
Oct 7, 2019 by Brian Orelli, PhDHere's Why Seattle Genetics Climbed 17.6% in SeptemberData from a pair of clinical trials sent shares of the oncology drugmaker higher.
Oct 7, 2019 by Brian Orelli, PhDHere’s Why Emergent BioSolutions Stock Climbed 19.4% in SeptemberThe bioterrorism expert finally completed its smallpox vaccine contract with the U.S. government.
Oct 7, 2019 by Brian Orelli, PhDHere's Why Alder Biopharmaceuticals More Than Doubled in SeptemberA Denmark-based drugmaker thought the biotech was too cheap to pass up.
Oct 7, 2019 by Brian Orelli, PhDHere's Why Akcea Therapeutics Jumped 30% TodayA licensing deal gives investors confidence in a turnaround.
Oct 5, 2019 by Brian Orelli, PhDHere’s Why Acceleron Pharma Stock Fell 12% in SeptemberThe biotech’s pipeline is shrinking, but investors should focus on what will drive near-term value.
Oct 4, 2019 by Brian Orelli, PhDHere's Why Acadia Pharmaceuticals Jumped 30.1% in SeptemberUnexpected phase 3 clinical trial data has investors smiling.
Oct 2, 2019 by Brian Orelli, PhDWinners and Losers of Europe’s Big Cancer MeetingUnfortunately, there were more of the latter.
Oct 1, 2019 by Brian Orelli, PhDThe Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's SuccessInvestors should go to the source.
Sep 30, 2019 by Brian Orelli, PhDHere’s Why Seattle Genetics Stock Jumped Higher TodaySolid data for two pipeline candidates increases investors' confidence in the cancer biotech.
Sep 26, 2019 by Brian Orelli, PhDHow Big Can This $8 Billion-Plus Diabetes Drug Class Get?GLP-1 drugs keep getting easier to take.
Sep 25, 2019 by Brian Orelli, PhDThe FDA Really Wants These Opioid Overdose Drugmakers to SucceedIn an unprecedented move, the agency is doing some of the legwork for the companies.
Sep 18, 2019 by Brian Orelli, PhDAn Investor's Guide to Disrupting DrugmakersPatents and monopolies don’t always go hand in hand.
Sep 16, 2019 by Brian Orelli, PhDHere’s Why Lexicon Pharmaceuticals Rose 18% TodayInvestors are jumping in ahead of a data presentation tomorrow.
Sep 12, 2019 by Brian Orelli, PhDHere's Why Adverum's Shares Saw a Lower Price TodayThe biotech’s gene therapy isn’t helping patients see better.
Sep 11, 2019 by Brian Orelli, PhDHere’s Why GW Pharmaceuticals Dropped 12% in AugustThe cannabis-focused biotech couldn’t hold its post-earnings gains.
